UNBS-1450

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 528304

CAS#: 676541-58-5

Description: UNBS-1450, also known as UBS-1450, is a sodium channel antagonist potentially for the treatment of cancer. UNBS-1450 is a hemi-synthetic cardenolide derived from 2″-oxovorusharin extracted from the plant Calotropis procera, which is effective against various cancer cell types with an excellent differential toxicity. At low nanomolar concentrations, UNBS-1450 induces apoptotic cell death. UNBS-1450 inhibits NF-κB transactivation and triggers apoptosis by cleavage of pro-caspases 8, 9 and 3/7, by decreasing expression of anti-apoptotic Mcl-1 and by recruitment of pro-apoptotic Bak and Bax protein eventually resulting in cell death.

Chemical Structure

img
UNBS-1450
CAS# 676541-58-5
Instruction

Theoretical Analysis

MedKoo Cat#: 528304
Name: UNBS-1450
CAS#: 676541-58-5
Chemical Formula: C31H43NO9S
Exact Mass: 605.27
Molecular Weight: 605.743
Elemental Analysis: C, 61.47; H, 7.16; N, 2.31; O, 23.77; S, 5.29

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: UNBS-1450, UNBS 1450, UNBS1450, UBS-1450, UBS1450, UBS 1450

IUPAC/Chemical Name: (1R,3aS,3bR,5aS,6aS,7aS,9R,11S,11aR,12aS,13aR,13bS,15aR)-3a,11a-dihydroxy-13a-(hydroxymethyl)-9,15a-dimethyl-1-(5-oxo-2,5-dihydrofuran-3-yl)icosahydro-1H-spiro[cyclopenta[7,8]phenanthro[2,3-b]pyrano[3,2-e][1,4]dioxine-11,2'-thiazolidin]-4'-one

InChi Key: GRINEMOQBRCRRY-OVGHKGCDSA-N

InChi Code: InChI=1S/C31H43NO9S/c1-16-11-30(32-24(34)14-42-30)31(37)26(39-16)40-22-10-18-3-4-21-20(28(18,15-33)12-23(22)41-31)5-7-27(2)19(6-8-29(21,27)36)17-9-25(35)38-13-17/h9,16,18-23,26,33,36-37H,3-8,10-15H2,1-2H3,(H,32,34)/t16-,18+,19-,20+,21-,22+,23+,26+,27-,28-,29+,30+,31-/m1/s1

SMILES Code: O=C1OCC([C@H]2CC[C@]3(O)[C@]4([H])CC[C@@]5([H])C[C@@]6([H])[C@](O[C@@]([C@@](O6)([H])O[C@H](C)C7)(O)[C@]7(SC8)NC8=O)([H])C[C@]5(CO)[C@@]4([H])CC[C@]23C)=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 605.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Schoner W, Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol. 2007 Aug;293(2):C509-36. Review. PubMed PMID: 17494630.

2: Cerella C, Muller F, Gaigneaux A, Radogna F, Viry E, Chateauvieux S, Dicato M, Diederich M. Early downregulation of Mcl-1 regulates apoptosis triggered by cardiac glycoside UNBS1450. Cell Death Dis. 2015 Jun 11;6:e1782. doi: 10.1038/cddis.2015.134. PubMed PMID: 26068790; PubMed Central PMCID: PMC4669823.

3: Muller F, Cerella C, Radogna F, Dicato M, Diederich M. Effects of Natural Products on Mcl-1 Expression and Function. Curr Med Chem. 2015;22(30):3447-61. Review. PubMed PMID: 26179996.

4: Juncker T, Cerella C, Teiten MH, Morceau F, Schumacher M, Ghelfi J, Gaascht F, Schnekenburger M, Henry E, Dicato M, Diederich M. UNBS1450, a steroid cardiac glycoside inducing apoptotic cell death in human leukemia cells. Biochem Pharmacol. 2011 Jan 1;81(1):13-23. doi: 10.1016/j.bcp.2010.08.025. PubMed PMID: 20849830.

5: Mijatovic T, Jungwirth U, Heffeter P, Hoda MA, Dornetshuber R, Kiss R, Berger W. The Na+/K+-ATPase is the Achilles heel of multi-drug-resistant cancer cells. Cancer Lett. 2009 Sep 8;282(1):30-4. doi: 10.1016/j.canlet.2009.02.048. PubMed PMID: 19339106.

6: Juncker T, Schumacher M, Dicato M, Diederich M. UNBS1450 from Calotropis procera as a regulator of signaling pathways involved in proliferation and cell death. Biochem Pharmacol. 2009 Jul 1;78(1):1-10. doi: 10.1016/j.bcp.2009.01.018. PubMed PMID: 19447218.

7: Mathieu V, Pirker C, Martin de Lassalle E, Vernier M, Mijatovic T, DeNeve N, Gaussin JF, Dehoux M, Lefranc F, Berger W, Kiss R. The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment. J Cell Mol Med. 2009 Sep;13(9B):3960-72. doi: 10.1111/j.1582-4934.2009.00708.x. PubMed PMID: 19243476; PubMed Central PMCID: PMC4516543.

8: Lefranc F, Mijatovic T, Kiss R. [The sodium pump could constitute a new target to combat glioblastomas]. Bull Cancer. 2008 Mar;95(3):271-81. doi: 10.1684/bdc.2008.0597. French. PubMed PMID: 18390407.

9: Lefranc F, Mijatovic T, Kondo Y, Sauvage S, Roland I, Debeir O, Krstic D, Vasic V, Gailly P, Kondo S, Blanco G, Kiss R. Targeting the alpha 1 subunit of the sodium pump to combat glioblastoma cells. Neurosurgery. 2008 Jan;62(1):211-21; discussion 221-2. doi: 10.1227/01.NEU.0000311080.43024.0E. PubMed PMID: 18300910.

10: Mijatovic T, Roland I, Van Quaquebeke E, Nilsson B, Mathieu A, Van Vynckt F, Darro F, Blanco G, Facchini V, Kiss R. The alpha1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers. J Pathol. 2007 Jun;212(2):170-9. PubMed PMID: 17471453.

11: Mijatovic T, De Nève N, Gailly P, Mathieu V, Haibe-Kains B, Bontempi G, Lapeira J, Decaestecker C, Facchini V, Kiss R. Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity. Mol Cancer Ther. 2008 May;7(5):1285-96. doi: 10.1158/1535-7163.MCT-07-2241. PubMed PMID: 18483316.

12: Lefranc F, Kiss R. The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas. Neoplasia. 2008 Mar;10(3):198-206. Review. PubMed PMID: 18323016; PubMed Central PMCID: PMC2259449.

13: Mijatovic T, Mathieu V, Gaussin JF, De Nève N, Ribaucour F, Van Quaquebeke E, Dumont P, Darro F, Kiss R. Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers. Neoplasia. 2006 May;8(5):402-12. PubMed PMID: 16790089; PubMed Central PMCID: PMC1592454.

14: Mijatovic T, Op De Beeck A, Van Quaquebeke E, Dewelle J, Darro F, de Launoit Y, Kiss R. The cardenolide UNBS1450 is able to deactivate nuclear factor kappaB-mediated cytoprotective effects in human non-small cell lung cancer cells. Mol Cancer Ther. 2006 Feb;5(2):391-9. PubMed PMID: 16505114.